Abstracts tagged "gout"

Abstract Number: 336 • 2019 ACR/ARP Annual Meeting
Treating Gout to Target Entails Renoprotective Effect in Patients with Moderate Chronic Kidney Disease
enrique Calvo-Aranda¹, Marta Novella-Navarro ², jOSE LUIS CABRERA-ALARCON ³, Francisco Aramburu ², Iustina Janta ⁴, Alejandro Prada-Ojeda ⁵, Luis Sala-Icardo ⁵, Maria del Carmen Ortega de la O ⁶, Cesar Diaz-Torne ⁷ and A. Urruticoechea-Arana ⁸, ¹Hospital Universitario Infanta Leonor, Madrid, Spain, ²Hospital Universitario HM Sanchinarro, madrid, Spain, ³Bioinformatica CNIC, madrid, Spain, ⁴Hospital General Universitario Gregorio Marañón, madrid, Spain, ⁵Hospital Universitario de Torrejon, madrid, Spain, ⁶Hospital Universitario Santa Elena, madrid, Spain, ⁷Hospital de la Santa Creu i Sant Pau, barcelona, Catalonia, Spain, ⁸HU Can Misses, Ibiza, Spain
Background/Purpose: Approximately 25% of patients with gouty arthritis suffer from chronic kidney disease (CKD). High serum uric acid (sUA) levels have been related to glomerular…
Abstract Number: 362 • 2019 ACR/ARP Annual Meeting
Methods to Efficiently Recruit Minority Patients with Gout for Clinic-Based Registries
Giovanni Adami¹, Giovanna Rosas ², Joshua Melnick ³, Jeffrey Foster ², Elizabeth Rahn ², Amy Mudano ⁴, Jeffrey Curtis ², Tony Merriman ⁵, S Louis Bridges ⁴ and Kenneth Saag ², ¹University of Verona, Verona, Italy, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmimgham, AL, ⁴University of Alabama at Birmingham, Birmingham, ⁵University of Otago, Birmingham, AL
Background/Purpose: Gout is frequently misdiagnosed and/or miscoded, making approaches to identifying eligible patients for observational and interventional studies more challenging. Ethnic and racial minorities are…
Abstract Number: 1240 • 2019 ACR/ARP Annual Meeting
A Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Anakinra in Difficult-To-Treat Acute Gouty Arthritis: The anaGO Study
Kenneth Saag¹, Alexander So ², Puja Khanna ³, Robert Keenan ⁴, Sven Ohlman ⁵, Torbjörn Kullenberg ⁵, Lisa Osterling Koskinen ⁵, Michael Pillinger ⁶ and Robert Terkeltaub ⁷, ¹University of Alabama at Birmingham, Birmingham, AL, ²Université de Lausanne, Lausanne, Switzerland, ³University of Michigan Medical School, Ann Arbor, ⁴Duke University School of Medicine, Durham, ⁵Sobi, Stockholm, Sweden, ⁶New York University School of Medicine, New York, ⁷San Diego VA/UCSD, San Diego, CA
Background/Purpose: In gout, urate crystals deposited in and around joints trigger episodes of acute arthritis, mediated by the proinflammatory cytokine IL-1β. In uncontrolled studies, the…
Abstract Number: 2892 • 2019 ACR/ARP Annual Meeting
Model-based Cost-Effectiveness Analyses Comparing Combinations of Urate Lowering Therapy and Anti-Inflammatory Treatment in Newly Diagnosed Gout Patients
Celine van de Laar¹, Martijn A.H. Oude Voshaar ², Carly Janssen ³, Matthijs Janssen ⁴, Maiwenn Al ⁵ and Mart A.F.J. van de Laar ⁶, ¹Transparency in Healthcare B.V., Hengelo, Overijssel, Netherlands, ²Transparency in Healthcare B.V. and Department of Psychology, Health & Technology, University of Twente, Hengelo, Netherlands, ³Department of Psychology, Health & Technology, University of Twente, Enschede, Netherlands, ⁴Department of Rheumatology, VieCuri Medical Center, Venlo, Netherlands, ⁵Erasmus University Rotterdam, Rotterdam, Netherlands, ⁶Arthritis Center Twente, Enschede, Netherlands
Background/Purpose: To assess the cost-effectiveness of various combinations of urate lowering therapy (ULT) and anti-inflammatory treatment in the management of newly diagnosed gout patients, from…
Abstract Number: 337 • 2019 ACR/ARP Annual Meeting
Gout in the US: Significant Association with Cardiovascular and Renal Disease Hospitalizations – A Nationwide Study
Alka Mithal ¹, Maanek Sehgal ² and Gurkirpal Singh¹, ¹ICORE, Woodside, ²UCLA, Los Angeles
Background/Purpose: Gout is a disorder of uric acid metabolism and often presents as acute severe joint pain. Previous work from our group suggests that all-cause…
Abstract Number: 363 • 2019 ACR/ARP Annual Meeting
Efficacy and Outcomes of Telephone-Based Management Program in Patients with Gout
Abdalhamid Al Harash¹, Tarun Sharma ¹, Brenda Dunmire ², Mary Chester Wasko ³ and William Ayoub ¹, ¹Allegheny Health Network, Pittsburgh, PA, ²AHN, Pittsburgh, PA, ³Allegheny Health Network-West Penn Hospital, Pittsburgh, PA
Background/Purpose: Gout is the most common inflammatory arthritis in the US, and causes significant morbidity. Despite published guidelines and available effective treatment, management remains suboptimal,…
Abstract Number: 1860 • 2019 ACR/ARP Annual Meeting
Using Electronic Visits (E-Visits) to Achieve Goal Serum Urate Levels in Patients with Gout in a Rheumatology Practice: A Pilot Study
Chio Yokose¹, April Jorge ¹, Kristin D'Silva ¹, Naomi Serling-Boyd ¹, Mark Matza ², Mazen Nasrallah ², Sarah Keller ¹, Amar Oza ¹, Hyon K. Choi ¹, Marcy Bolster ¹ and Deborah Collier ¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston
Background/Purpose: Gout is a highly prevalent form of inflammatory arthritis associated with increased morbidity and mortality, and the burden of gout on the healthcare system…
Abstract Number: 339 • 2019 ACR/ARP Annual Meeting
Depressive Symptoms Influence Success of Allopurinol in Reducing Serum Urate
Sylvie Mrug ¹, Catheryn Orihuela ¹, Elizabeth Rahn ², Amy Mudano ¹, Kenneth Saag ², Jeffrey Foster ² and Angelo Gaffo², ¹University of Alabama at Birmingham, Birmingham, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Elevated levels of serum urate (sUA) are central to the pathogenesis of gout and have been associated with cardiovascular disease. Urate-lowering therapies are effective…
Abstract Number: 1168 • 2019 ACR/ARP Annual Meeting
Frequently Encountered Artifacts in Novel Application of Dual-Energy CT to Vascular Imaging: A Pilot Study
Chio Yokose¹, Sterling Eide ², F. Joseph Simeone ¹, Kam Shojania ³, Savvas Nicolaou ⁴, Fabio Becce ⁵ and Hyon K. Choi ¹, ¹Massachusetts General Hospital, Boston, MA, ²National University Hospital of Singapore, Singapore, Singapore, ³Vancouver General Hospital, Vancouver, Canada, ⁴Vancouver General Hospital, Vancouver, BC, Canada, ⁵Lausanne University Hospital, Lausanne, Switzerland
Background/Purpose: One hypothesized link between cardiovascular disease and gout is the direct deposition of monosodium urate (MSU) crystals in atherosclerotic plaque. A 2018 ACR abstract…
Abstract Number: 1987 • 2019 ACR/ARP Annual Meeting
CCN3 Regulates Macrophage Function in MSU-induced Inflammation
Lihua Duan¹, Jie Chen ¹ and Jixin Zhong ², ¹Department of Rheumatology and Clinical Immunology, Jiangxi Provincial People's Hospital, Nanchang, Jiangxi, China (People's Republic), ²Cardiovascular Research Institute, School of Medicine, Case Western Reserve University, Cleveland, OH
Background/Purpose: Gout is the most common metabolic disease in which monosodium urate (MSU) crystals form and deposit in the joints and soft tissues of patients.…
Abstract Number: 340 • 2019 ACR/ARP Annual Meeting
Increased Physical Activity in Gout Patients Correlates with Better Prognosis, Decreased Pain, and Suppressed C-Reactive Protein Levels
Naomi Schlesinger¹, Kyle Jablonski ², Peter Harb ³, Caitlin Henry ³, Emily Schwarz ³, Ifeoma Okafor ³, Wael Jarjour ⁴ and Nicholas Young ⁵, ¹Rutgers Health- RWJ Medical School, New Brunswick, NJ, ²The Ohio State University Wexner Medical Center, Division of Immunology and Rheumatology, Columbus, ³Ohio State College of Medicine, Columbus, ⁴Ohio State College of Medicine, Columbus, OH, ⁵The Ohio State University Wexner Medical Center, Division of Immunology and Rheumatology, Columbus, OH
Background/Purpose: Regular exercise programs were previously thought to be inappropriate in patients with rheumatic diseases because of the potential to exacerbate inflammation. However, while recent paradigm-shifting…
Abstract Number: 1216 • 2019 ACR/ARP Annual Meeting
Pilot, Randomized, Double-Blinded, Placebo Controlled Efficacy AndSafety Study of a Transdermal Alkalinizing and Pain Relieving Treatment ForAcute Gout Flare
Smitha Reddy¹, Ray Mabaquiao ² and Lisa Misell ³, ¹Arthritis Care and Research Inc., Poway, CA, ²Triwest Research, El Cajon, CA, ³Dyve Biosciences, San Diego, CA
Background/Purpose: Gout is characterized by a build-up of uric acid crystals in and around the joints. Uric acid crystal formation and dissolution is affected by…
Abstract Number: 2047 • 2019 ACR/ARP Annual Meeting
Time-trends in Opioid Use Hospitalizations in Common Musculoskeletal Conditions: Gout, Osteoarthritis, Rheumatoid Arthritis, Fibromyalgia, and Low Back Pain
Jasvinder Singh¹ and John Cleveland ², ¹University of Alabama Medical Center, Birmingham, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Rates of opioid abuse and associated mortality is a problem of epidemic proportion in the U.S. To our knowledge, limited data are available on…
Abstract Number: 341 • 2019 ACR/ARP Annual Meeting
Development of a Multivariable Improvement Measure for Gout
Naomi Schlesinger¹, N. Lawrence Edwards ², Anthony Yeo ³ and Peter Lipsky ⁴, ¹Division of Rheumatology, Department of Medicine, Rutgers, The State University of New Jersey, New Brunswick, NJ, ²Department of Medicine, University of Florida, Gainesville, FL, ³Horizon Therapeutics plc, Lake Forest, IL, ⁴AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: Gout is a multifactorial inflammatory disease in which patients experience a wide range of signs and symptoms, including flares, inflammatory arthritis, tophi and disability.…
Abstract Number: 1217 • 2019 ACR/ARP Annual Meeting
Phase 2 Dose-ranging Study of SEL-212 in Symptomatic Gout Patients: Selection of Doses for Further Clinical Development
Rehan Azeem¹, Alan Kivitz ², Horacio Plotkin ¹, Lloyd Johnston ¹, Takashi K. Kishimoto ¹, Justin Park ¹, Stephen Smolinski ¹ and Wesley DeHaan ¹, ¹Selecta Biosciences, Watertown, MA, ²Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: Gout is caused by the deposition of monosodium urate (MSU) crystals in joints due to chronic hyperuricemia. Long-term treatment focuses on reducing serum uric…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].